Neurol India Home 
 

NI FEATURE: THE FIRST IMPRESSION
Year : 2020  |  Volume : 68  |  Issue : 2  |  Page : 243-

The Cover Page

 

Correspondence Address:




How to cite this article:
. The Cover Page.Neurol India 2020;68:243-243


How to cite this URL:
. The Cover Page. Neurol India [serial online] 2020 [cited 2020 Jun 1 ];68:243-243
Available from: http://www.neurologyindia.com/text.asp?2020/68/2/243/284362


Full Text

[AUTHOR:1]

The incredibly fast development of a molecular diagnostic test for COVID-19 has allowed a timely response to the pandemic by testing and isolating infected patients to prevent further spread.

Translational Health Science and Technology Institute (THSTI), an autonomous institute of DBT is established with the mandate of finding solutions for large and unique public health problems. Being situated in the NCR bio-cluster, THSTI boasts of a team with expertise in the multifarious discipline and an inter-institutional ecosystem. THSTI has grown from an idea to an institution that is ready to take its place with leading scientific institutions in the country but differentiates itself by being aimed beyond discovery research, to the fostering of application through its efforts and partnerships. THSTI has five areas identified as 'star' projects where we will develop world-class research and translational programmes. These are i) vaccines, ii) maternal and child health, iii) point-of-care diagnostics, iv) metabolic diseases and nutrition, and v) training in clinical and product development. THSTI has initiated expedited research and development on Covid-19 diagnostics, vaccines and drug development with a multidisciplinary team of faculty and supported by a wide network of clinical partners.

Inset shows the image of SARS-CoV-2 taken from CDC's public health image library.

Photo credits:

Dr Susmita Chaudhuri, Assistant Professor, THSTI, Co-Founder: Tritek Innovation Pvt. Ltd.

Inset: CDC/Alissa Eckert, MS; Dan Higgins, MAMSA